Advertisement

Investigational New Drugs

, 27:319 | Cite as

p53-dependent antiproliferative and antitumor effect of novel alkyl series of diorganotin(IV) compounds

  • Biplob Koch
  • Tushar S. Basu Baul
  • Anupam ChatterjeeEmail author
PRECLINICAL STUDIES

Summary

Purpose: A series of diorganotin(IV) dichloride complexes of N-(2-pyridylmethylene)arylamine (nitrogen-chelating ligands) have been synthesized and characterized. The present study was carried out to investigate the comparative anti-proliferative and anti-tumor effect of Me2SnCl2.L1 (OTC-1), Et2SnCl2.L2 (OTC-2) and nBu2SnCl.L2 (OTC-3) in combination with X-rays (1.5 Gy). Method: The cytotoxicity of these diorganotin(IV) compounds was studied in human peripheral lymphocytes and the antitumor activity was assessed in Dalton’s lymphoma cells. The involvement of proteins that regulate cell cycle and apoptosis was investigated to elucidate the mechanism of their action. Results: 5 mg kg−1 of OTC-3 showed better antiproliferative and antitumor activity than OTC-1 and OTC-2, both as alone or in combination with X-rays. The maximum enhancement of exchange aberrations and the level of p53 and p16 proteins were observed in the OTC-3 treated samples. Upregulated expression of p53 caused a significant down-regulated transcriptionally repression of Survivin in OTC-3 treated human lymphocytes. Conclusion: It could be possible that after treatment with either OTC-3 alone or in combination with X-rays the Dalton’s lymphoma cells may die apoptotically after inducing initial delay in cell cycle and thereby survivality of mouse bearing Dalton’s Lymphoma cells was increased significantly.

Keywords

Diorganotin(IV) Antiproliferation Anti-tumor Apoptosis 

Notes

Acknowledgements

This work was supported partly by grants from the Council of Scientific and Industrial Research, New Delhi, India (Grant No. 9/347(118)/97/EMR-I) and partly by grants from the University Potential for Excellence Programme from University Grants Commission, New Delhi to AC and from the Department of Science and Technology, New Delhi, India (Grant No. SR/SI/IC-03/2005) to TSBB.

References

  1. 1.
    Pellerito L, Nagy L (2002) Organotin(IV)n+ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects. Coord Chem Rev 224:111–150. doi: 10.1016/S0010-8545(01)00399-X CrossRefGoogle Scholar
  2. 2.
    Gielen M, Tiekink ERT (eds) (2005) Metallotherapeutic D and metal-based diagnostic agents: 50SnTin compounds and their therapeutic potential. Wiley, Chichester, pp 421–439Google Scholar
  3. 3.
    Li Q, Yang P, Wang H, Guo M (1996) Diorganotin(IV) antitumor agent. (C2H5)2SnCl2 (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies. J Inorg Chem 15;64(3):181–195Google Scholar
  4. 4.
    Crowe AJ (1987) The chemotherapeutic properties of tin compounds. Drugs Future 12:255–275Google Scholar
  5. 5.
    Gielen M, Willem R, Bouhdid A, De Vos D, Kuiper CM, Veerman G et al (1995) In vitro antiproliferation effects, toxicity profiles in vivo in mice and antitumor activity in tumor bearing mice of five diorganotin compounds. In Vivo 9:59–64PubMedGoogle Scholar
  6. 6.
    Crowe AJ, Smith PJ, Cardin CJ, Parge HE, Smith FE (1984a) Possible predissociation of diorganotin dihalide complexes: relationship between antitumor activity and structure. Cancer Lett 24:45–58. doi: 10.1016/0304-3835(84)90078-8 PubMedCrossRefGoogle Scholar
  7. 7.
    Crowe AJ, Smith PJ, Atassi G (1984b) Investigations into the antitumor activity of organotin compounds. 2. Diorganotin dihalide and dipseudohalide complexes. Inorg Chim Acta 93:179–184. doi: 10.1016/S0020-1693(00)88160-8 CrossRefGoogle Scholar
  8. 8.
    Basu Baul S, Basu Baul TS, Rivarola E, Dakternieks D, Tiekink ERT, Syng-ai C et al (1998) Synthesis and characterization of diorganotin(IV) complexes of N-(2-Pyridylmethylene)-arylamines and Mutagenecity testing of Et2SnCl2.L4. Appl Organomet Chem 12:503–513. L4 = N-(2-Pyridylmethylene)-4-toluidine. doi: 10.1002/(SICI)1099-0739(199807)12:7<503::AID-AOC746>3.0.CO;2-P CrossRefGoogle Scholar
  9. 9.
    Koch B, BasuBaul TS, Chatterjee A (2008) Cell Proliferation inhibition and antitumor activity of novel alkyl series of diorganotin(IV) compounds. J Appl Toxicol 28:430–438. doi: 10.1002/jat.1290 PubMedCrossRefGoogle Scholar
  10. 10.
    Syng-ai C, Basu Baul T, Chatterjee A (2002) Antiproliferative and cytotoxic effect of a novel organotin compound on mammalian cells both in vitro and in vivo. Mutat Res 513:49–59PubMedGoogle Scholar
  11. 11.
    Einhorn N, Trope C, Ridderhiem M, Boman K, Sorbe B, Cavallin-Stahl EA (2003) Systematic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta Oncol (Madr) 42:546–556. doi: 10.1080/02841860310014660 CrossRefGoogle Scholar
  12. 12.
    Goto K, Akematsu T, Shimagu H, Suigiyama T (1975) Simple differential Giemsa staining of sister chromatids after treatment with photosensitive dyes and exposure to light and the mechanism of staining. Chromosoma 53:223–230. doi: 10.1007/BF00329173 PubMedCrossRefGoogle Scholar
  13. 13.
    McFee AF, Sayer AM, Salomaa SI, Lindholm C, Littlefield LG (1997) Methods for improving the yield and quality of metaphase preparations for FISH probing of human lymphocyte chromosomes. Environ Mol Mutagen 29:98. doi: 10.1002/(SICI)1098-2280(1997)29:1<98::AID-EM13>3.0.CO;2-C PubMedCrossRefGoogle Scholar
  14. 14.
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85. doi: 10.1016/0003-2697(85)90442-7 PubMedCrossRefGoogle Scholar
  15. 15.
    Cornforth MN, Bedford JS (1993) Ionizing radiation damage and its early development in chromosomes. In: Lett JT, Sinclair WK (eds) Advances in Radiation Biology, Vol. 17: DNA Damage Caused by Radiation. Academic, LondonGoogle Scholar
  16. 16.
    Al-Imara L, Salaman MR, Sljivic VS, Poller RC (1993) Inhibition of mouse spleen cell activity by organotin compounds: effect of attachment to a maltose residue to the organotin group. Int J Immunopharmacol 15:287–291PubMedCrossRefGoogle Scholar
  17. 17.
    De Santiago A, Aguilar-Santelises M (1999) Organotin compounds decrease in vitro survival, proliferation and differentiation of normal human B lymphocytes. Hum Exp Toxicol 18:619–624. doi: 10.1191/096032799678839437 PubMedCrossRefGoogle Scholar
  18. 18.
    Pellerito L, Nagy L (2002) Organotin(IV)n+ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects. Coord Chem Rev 224:111–150. doi: 10.1016/S0010-8545(01)00399-X CrossRefGoogle Scholar
  19. 19.
    Rudoltz MS, Kao G, Blank KR, Muschel RJ, McKenna WG (1996) Molecular biology of the cell cycle: potential for therapeutic applications in radiation oncology. Semin Radiat Oncol 6:284–294. doi: 10.1016/S1053-4296(96)80024-5 PubMedCrossRefGoogle Scholar
  20. 20.
    Bassi L, Carloni M, Meschini R, Fonti E, Palitti F (2003) X-irradiated human lymphocytes with unstable aberrations and their preferential elimination by p53/surviving-dependent apoptosis. Int J Radiat Biol 79:1–12. doi: 10.1080/713864981 CrossRefGoogle Scholar
  21. 21.
    Stridh H, Orrenius S, Hampton MB (1999) Caspase involvement in the induction of apoptosis by the environmental toxicants tributyltin and triphenyltin. Toxicol Appl Pharmacol 156:141–146. doi: 10.1006/taap.1999.8633 PubMedCrossRefGoogle Scholar
  22. 22.
    Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the anti-apoptotic surviving gene by wild type p53. J Biol Chem 277:3247–3257. doi: 10.1074/jbc.M106643200 PubMedCrossRefGoogle Scholar
  23. 23.
    Deveraux QL, Reed JC (1999) IAP family proteins-suppressor of apoptosis. Genes Dev 13:1253–1262. doi: 10.1101/gad.13.3.239 CrossRefGoogle Scholar
  24. 24.
    Cookson MR, Slamon ND, Pentreath VW (1998) Glutathione modifies the toxicity of triethyltin and trimethyltin in C6 glioma cells. Arch Toxicol 72(4):197–202. doi: 10.1007/s002040050488 PubMedCrossRefGoogle Scholar
  25. 25.
    Rekker RF (1977) The hydrophobic fragmental constant. Elsevier, AmsterdamGoogle Scholar
  26. 26.
    Anon. Guidelines for the testing of Chemicals for Mutagenicity, Report on Health and Social Subjects, No. 35, Department of Health, HMSO, London, 1989Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Biplob Koch
    • 1
  • Tushar S. Basu Baul
    • 2
  • Anupam Chatterjee
    • 3
    Email author
  1. 1.Genetics Laboratory, Department of ZoologyNorth-Eastern Hill UniversityShillongIndia
  2. 2.Department of ChemistryNorth-Eastern Hill UniversityShillongIndia
  3. 3.Genetics Laboratory, Department of Biotechnology and BioinformaticsNorth-Eastern Hill UniversityShillongIndia

Personalised recommendations